This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Close Message
NextPharmaJob.com for pharmaceutical industry jobs
Envision your future with us
NextPharmaJob.com is dedicated to putting job seekers looking for pharmaceutical industry jobs in touch with recruiters and employers.
Browse Jobs Search Jobs

To receive a FREE weekly email alert of all the latest pharmaceutical industry jobs added to our database enter your email address below.

Submit | Tell me more...

Sister sites:
Our sister site Our sister site
Partner sites:

At Burntsky Limited we work with a number of third parties in order to maximise the reach of the jobs posted with us including but not limited to:

JooblePartner Jooble
UK Jobs
Science Jobs

Industry News
Back

Oblique Therapeutics has been Recognized as one of the 15 Most Promising Biotech Startups in Europe 2019, by StartUp City Magazine

GOTHENBURG, Sweden, July 17, 2019 /PRNewswire/ -- Oblique Therapeutics, a Swedish biotech focusing on generating novel therapeutic antibodies towards severe diseases such as cancer and pain, has been honored as one of the most promising biotech startup in Europe 2019 by StartUp City magazine. An interview with the CEO, Owe Orwar, is featured on the cover story of the BioTech special issue published this month.

StartUp City Magazine: "Oblique Therapeutics is uncovering medical breakthroughs in antibody therapeutics using its proporietary technology platform AbiprotTM". The AbiprotTM technology enables the development of antibodies against difficult-to-drug targets such as ion channels and certain G-protein-coupled receptors (GPCRs) that can translate into new effective treatment options for large groups of patients in need of new medicines.

"It is an honor to receive this recognition, and we are devoted to continue on building and advancing our pipeline with new antibody therapeutics that matters to patients," says Owe Orwar, CEO

The article can be accessed from: Biotech-startup

About Oblique Therapeutics

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises three in-house programs - two antibody candidates: aKRAS in advanced cancer, aTRPA1 in pain; and the small molecule OT-1096 in triple-negative breast cancer. In addition, there are three antibodies programs in collaboration with pharma. Oblique Therapeutics makes medicines that matter to patients. http://obliquet.com/

For more information, please contact:
Owe Orwar, CEO
Email: owe@obliquet.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oblique-therapeutics-ab/r/oblique-therapeutics-has-been-recognized-as-one-of-the-15-most-promising-biotech-startups-in-europe-,c2864894

The following files are available for download:



Back | Next Story: The Leukemia & Lymphoma Society's Silicon Valley & Monterey Bay Area Chapter Announces Local 2019 Man & Woman of the Year Winners
line graphic

Compatible with:

JobMate   Broadbean   Idibu

Site optimised for Internet Explorer 8+ / Firefox 3+
View a complete Jobs Listing




Credit cards image